INM - InMed Pharmaceuticals Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

INM

INMED PHARMACEUTICALS INC.

NASDAQ

$1.38

▼ DOWN 3.50% (-0.05)

KEY STATISTICS

Market Cap$2.50 M

52w High$2.50

52w Low$0.57

Dividend Yield—

Frequency—

P/E-0.25

Volume111.85K

Shares Out.1.81M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Eric A. Adams Chem.

COMPENSATION 2026

Salary$301,630

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$396,973

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 5, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateSep 23, 2026

DayWednesday

Rev. Est.—

SEP

WED

SPLIT RECORD

DATE	TYPE	RATIO
2024-11-14	Reverse	1:20
2022-09-07	Reverse	1:25
2020-07-06	Reverse	1:33

PRICE

$1.38 ▼ DOWN 3.50% (−$0.05)

OVERLAYS

About InMed Pharmaceuticals Inc.

https://www.inmedpharma.com ↗

InMed Pharmaceuticals Inc. is a Vancouver-based clinical-stage company developing cannabinoid-based therapies, including topical, ocular, and pain treatments, with products in various clinical and preclinical stages.

INDUSTRY

Biotechnology

A PRODUCT INMED PHARMACEUTICALS INC. IS KNOWN FOR

BayMedica Rare Cannabinoids (CBC, d9-THCV, CBDV, CBTC)

InMed's subsidiary BayMedica manufactures and sells high-purity, bioidentical rare cannabinoids as raw ingredients for the health and wellness industry, generating revenue while its pharmaceutical candidates are in clinical development.